Many BET inhibitors are currently in clinical trials for cancer, and repurposing them against EBV may be useful in treating lytic replication during infectious mononucleosis and post-transplantation lymphoproliferative disorder. This evidence concerns the gene DNER and lymphoproliferative syndrome.